Chemokine receptor CCR1 antagonist CCX354-C treatment for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical trial

Annals of the Rheumatic Diseases

Volumn 72, Issue 3, 2013, Pages 337-344

  Tak, Paul P ^a,b   Balanescu, Andra ^c   Tseluyko, Vira ^d   Bojin, Silvia ^e   Drescher, Edit ^f   Dairaghi, Dan ^g   Miao, Shichang ^g   Marchesin, Vittorio ^g   Jaen, Juan ^g   Schall, Thomas J ^g   Bekker, Pirow ^g  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b GLAXOSMITHKLINE   (United Kingdom)

^c St Maria Hospital   (Romania)

^d City Clinical Hospital   (Ukraine)

^e Spitalul Judetean de Urgenta Dr Fogolyan Kristof   (Romania)

^f Veszprém Megyei Csolnoky Ferenc Egyetemi Oktató Kórház   (Hungary)

^g ChemoCentryx Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CARBOXY TERMINAL TELOPEPTIDE; CCX354 C; CD20 ANTIBODY; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR1; GLUCOCORTICOID; METHOTREXATE; OSTEOCALCIN; PLACEBO; RHEUMATOID FACTOR; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ANGINA PECTORIS; ARTHRALGIA; ARTICLE; BLEEDING; BONE TURNOVER; BRONCHITIS; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DISEASE ACTIVITY; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; FOOT PAIN; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN CELL; LEUKOCYTURIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; MUSCLE SPASM; NAUSEA; OROPHARYNX PAIN; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SIDE EFFECT; SUBUNGAL HEMORRHAGE; SYSTOLIC BLOOD PRESSURE; URINARY TRACT INFECTION; URTICARIA; VOMITING;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; RECEPTORS, CCR1; TREATMENT OUTCOME;

EID: 85028106569     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2011-201605     Document Type: Article

References (31)

1. Hamilton JA, Tak P P. The dynamics of macrophage lineage populations in inflammatory and autoimmune diseases. Arthritis Rheum 2009;60:1210-21.
2. Bresnihan B. Pathogenesis of joint damage in rheumatoid arthritis. J Rheumatol 1999;26:717-19.
3. Kinne RW, Bräuer R, Stuhlmüller B, et al. Macrophages in rheumatoid arthritis. Arthritis Res 2000;2:189-202.
4. Kunkel SL, Lukacs N, Kasama T, et al. The role of chemokines in inflammatory joint disease. J Leukoc Biol 1996;59:6-12.
5. Szekanecz Z, Koch AE. Update on synovitis. Curr Rheumatol Rep 2001;3: 53-63.
6. Haringman JJ, Kraan MC, Smeets TJ, et al. Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis. Ann Rheum Dis 2003;62:715-21.
7. Haringman JJ, Smeets TJ, Reinders-Blankert P, et al. Chemokine and chemokine receptor expression in paired peripheral blood mononuclear cells and synovial tissue of patients with rheumatoid arthritis, osteoarthritis, and reactive arthritis. Ann Rheum Dis 2006;65:294-300.
8. Berahovich RD, Miao Z, Wang Y, et al. Proteolytic activation of alternative CCR1 ligands in inflammation. J Immunol 2005;174:7341-51.
9. Lebre MC, Vergunst CE, Choi I Y, et al. Why CCR2 and CCR5 blockade failed and why CCR1 blockade might still be effective in the treatment of rheumatoid arthritis. PLoS ONE 2011;6:e21772.
10. Fuller K, Owens JM, Chambers TJ. Macrophage inflammatory protein-1 alpha and IL-8 stimulate the motility but suppress the resorption of isolated rat osteoclasts. J Immunol 1995;154:6065-72.
11. Scheven BA, Milne JS, Hunter I, et al. Macrophage-inflammatory protein-1alpha regulates preosteoclast differentiation in vitro. Biochem Biophys Res Commun 1999;254:773-8.
12. Yu X, Huang Y, Collin-Osdoby P, et al. CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts. J Bone Miner Res 2004;19: 2065-77.
13. Dairaghi DJ, Zhang P, Wang Y, et al. Pharmacokinetic and pharmacodynamic evaluation of the novel CCR1 antagonist CCX354 in healthy human subjects: implications for selection of clinical dose. Clin Pharmacol Ther 2011;89: 726-34.
14. Sokka T, Pincus T. Quantitative joint assessment in rheumatoid arthritis. Clin Exp Rheumatol 2005;23(5 Suppl 39):S58-62.
15. Choy E, Sattar N. Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis 2009;68:460-9.
16. Lean JM, Murphy C, Fuller K, et al. CCL9/MIP-1gamma and its receptor CCR1 are the major chemokine ligand/receptor species expressed by osteoclasts. J Cell Biochem 2002;87:386-93.
17. Vallet S, Raje N, Ishitsuka K, et al. MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. Blood 2007;110:3744-52.
18. Oba Y, Lee JW, Ehrlich LA, et al. MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells. Exp Hematol 2005;33:272-8.
19. Garnero P, Shih WJ, Gineyts E, et al. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994;79: 1693-700.
20. McClung MR, Lewiecki EM, Cohen SB, et al.; AMG 162 Bone Loss Study Group. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006;354:821-31.
21. Borregaard J, Skov L, Wang L, et al. Evaluation of the effect of the specific CCR1 antagonist CP-481715 on the clinical and cellular responses observed following epicutaneous nickel challenge in human subjects. Contact Derm 2008;59: 212-19.
22. Clucas AT, Shah A, Zhang YD, et al. Phase I evaluation of the safety, pharmacokinetics and pharmacodynamics of CP-481,715. Clin Pharmacokinet 2007;46:757-66.
23. Reuss R, Schreiber V, Klein A, et al. No significant effect of orally administered chemokine receptor 1 antagonist on intercellular adhesion molecule-3 expression in relapsing-remitting multiple sclerosis patients. Mult Scler 2010;16:366-9.
24. Zipp F, Hartung H P, Hillert J, et al.; CCR1 Antagonist Study Group. Blockade of chemokine signaling in patients with multiple sclerosis. Neurology 2006;67: 1880-3.
25. Kerstjens HA, Bjermer L, Eriksson L, et al. Tolerability and efficacy of inhaled AZD4818, a CCR1 antagonist, in moderate to severe COPD patients. Respir Med 2010;104:1297-303.
26. Vergunst CE, Gerlag DM, von Moltke L, et al. MLN3897 plus methotrexate in patients with rheumatoid arthritis: safety, efficacy, pharmacokinetics, and pharmacodynamics of an oral CCR1 antagonist in a phase IIa, double-blind, placebo-controlled, randomized, proof-of-concept study. Arthritis Rheum 2009;60:3572-81.
27. Schall TJ, Proudfoot AE. Overcoming hurdles in developing successful drugs targeting chemokine receptors. Nat Rev Immunol 2011;11:355-63.
28. van Kuijk AW, Vergunst CE, Gerlag DM, et al. CCR5 blockade in rheumatoid arthritis: a randomised, double-blind, placebo-controlled clinical trial. Ann Rheum Dis 2010;69:2013-16.
29. Vergunst CE, Gerlag DM, Lopatinskaya L, et al. Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2008;58:1931-9.
30. Szekanecz Z, Koch AE, Tak P P. Chemokine and chemokine receptor blockade in arthritis, a prototype of immune-mediated inflammatory diseases. Neth J Med 2011;69:356-66.
31. Walters MJ, Wang Y, Lai N, et al. Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease. J Pharmacol Exp Ther 2010;335:61-9.